Diplomat Pharmacy, Inc. (NYSE:DPLO) – Equities researchers at Leerink Swann upped their FY2019 earnings per share (EPS) estimates for Diplomat Pharmacy in a research note issued to investors on Monday. Leerink Swann analyst D. Larsen now anticipates that the company will post earnings of $1.05 per share for the year, up from their previous forecast of $0.86. Leerink Swann has a “Outperform” rating and a $23.00 price objective on the stock.

Other research analysts have also issued research reports about the company. BidaskClub lowered Diplomat Pharmacy from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, October 17th. Needham & Company LLC raised their price objective on Diplomat Pharmacy from $23.75 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, November 8th. Robert W. Baird reaffirmed a “buy” rating and set a $20.00 price objective on shares of Diplomat Pharmacy in a research report on Sunday, September 17th. Deutsche Bank started coverage on Diplomat Pharmacy in a research report on Monday, December 4th. They set a “buy” rating and a $22.00 price objective for the company. Finally, Mizuho set a $16.00 price objective on Diplomat Pharmacy and gave the company a “hold” rating in a research report on Tuesday, October 24th. Five analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $20.72.

Diplomat Pharmacy (DPLO) traded up $0.39 during mid-day trading on Wednesday, reaching $20.26. The company had a trading volume of 675,424 shares, compared to its average volume of 806,388. Diplomat Pharmacy has a one year low of $12.25 and a one year high of $21.99. The company has a current ratio of 1.34, a quick ratio of 0.82 and a debt-to-equity ratio of 0.18. The company has a market cap of $1,338.90, a price-to-earnings ratio of 25.25, a PEG ratio of 3.50 and a beta of 0.61.

Diplomat Pharmacy (NYSE:DPLO) last posted its quarterly earnings data on Monday, November 6th. The company reported $0.25 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.15 by $0.10. Diplomat Pharmacy had a return on equity of 8.30% and a net margin of 0.18%. The company had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.16 billion. During the same quarter last year, the company earned $0.21 EPS. The firm’s revenue for the quarter was down 4.8% on a year-over-year basis.

In other news, President Joel Saban purchased 10,000 shares of the company’s stock in a transaction dated Monday, November 20th. The shares were purchased at an average cost of $15.24 per share, for a total transaction of $152,400.00. Following the purchase, the president now directly owns 12,000 shares in the company, valued at approximately $182,880. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Jeffrey G. Park purchased 3,000 shares of the company’s stock in a transaction dated Monday, November 20th. The stock was purchased at an average price of $15.46 per share, for a total transaction of $46,380.00. Following the completion of the purchase, the director now owns 7,640 shares in the company, valued at $118,114.40. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 15,000 shares of company stock worth $228,780. Company insiders own 30.20% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in DPLO. Schwab Charles Investment Management Inc. lifted its position in Diplomat Pharmacy by 5.5% during the first quarter. Schwab Charles Investment Management Inc. now owns 163,769 shares of the company’s stock valued at $2,613,000 after purchasing an additional 8,550 shares in the last quarter. Bank of Montreal Can lifted its position in Diplomat Pharmacy by 3.0% during the second quarter. Bank of Montreal Can now owns 11,600 shares of the company’s stock valued at $172,000 after purchasing an additional 340 shares in the last quarter. Louisiana State Employees Retirement System lifted its position in Diplomat Pharmacy by 0.6% during the second quarter. Louisiana State Employees Retirement System now owns 17,800 shares of the company’s stock valued at $263,000 after purchasing an additional 100 shares in the last quarter. Aperio Group LLC lifted its position in Diplomat Pharmacy by 38.7% during the second quarter. Aperio Group LLC now owns 19,793 shares of the company’s stock valued at $293,000 after purchasing an additional 5,526 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its position in Diplomat Pharmacy by 478.4% during the second quarter. Russell Investments Group Ltd. now owns 14,600 shares of the company’s stock valued at $216,000 after purchasing an additional 12,076 shares in the last quarter. Hedge funds and other institutional investors own 72.48% of the company’s stock.

WARNING: This story was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/12/13/fy2019-eps-estimates-for-diplomat-pharmacy-inc-dplo-increased-by-analyst.html.

About Diplomat Pharmacy

Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.

Earnings History and Estimates for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.